

DR. YONG HE (Orcid ID : 0000-0003-4123-894X)

Received Date : 04-Dec-2019

Revised Date : 17-Mar-2020

Accepted Date : 28-Mar-2020

Article type : Research Article

## Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction

Rui Han<sup>1†</sup>, Shuai Hao<sup>1†</sup>, Conghua Lu<sup>1†</sup>, Chong Zhang<sup>2</sup>, Caiyu Lin<sup>1</sup>, Li Li<sup>1</sup>, Yubo Wang<sup>1</sup>, Chen Hu<sup>1</sup>, Yong He<sup>1\*</sup>

### Affiliations:

<sup>1</sup> Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China

<sup>2</sup> Department of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China

† These authors contributed equally to this work

\* **Corresponding author:** Yong He, Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China. Phone: 86-23-68757791; Fax: 86-23-68757791;

E-mail: heyong@tmmu.edu.cn

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/1878-0261.12682](https://doi.org/10.1002/1878-0261.12682)

Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

---

**Running title:** Aspirin sensitizes osimertinib-resistant NSCLC cells.

**Key words:** osimertinib, aspirin, resistance, EGFR-TKI, apoptosis

**Abbreviations**

NSCLC, non-small cell lung cancer, EGFR-TKI, Epidermal growth factor receptor- tyrosine kinase inhibitor, siRNA, small-interfering RNA

---

## Abstract

Osimertinib, a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), provides marked clinical benefit for patients with EGFR-activating mutations. Unfortunately, limited treatments exist for patients who acquire osimertinib resistance. We observed two “special” patients who regained an antitumor response with osimertinib plus aspirin treatment. As previous data indicate that aspirin induces anti-proliferative effects in tumor cells, we designed a preclinical study to explore whether aspirin combined with osimertinib could synergistically sensitize osimertinib-resistant NSCLC cells. The effects of combined treatment with osimertinib and aspirin on osimertinib-resistant non-small-cell lung cancer (NSCLC) cell lines were examined *in vitro* and *in vivo*. The combination of osimertinib and aspirin induced strong anti-proliferative and proapoptotic effects in osimertinib-resistant NSCLC cells through inhibition of Akt/FoxO3a signaling component phosphorylation and increased Bim expression. Furthermore, Bim knockdown by siRNA significantly attenuated osimertinib resensitization by aspirin. *In vivo*, combination of aspirin and osimertinib significantly decreased tumor growth of PC-9GROR cell xenografts. Data of patients with NSCLC who received osimertinib treatment at Daping Hospital between January 2015 and January 2019 were reviewed retrospectively. According to clinical data for 45 patients with NSCLC, retrospective analysis showed that the median progression-free survival (PFS) was significantly longer in the osimertinib plus aspirin group than in the osimertinib group. In summary, aspirin synergistically enhances the antitumor activity of osimertinib in osimertinib-resistant lung cancer cells through promoting Bim-dependent apoptosis. This combination therapy may be effective in overcoming acquired resistance to osimertinib and prolonging survival in patients with NSCLC.

---

## Introduction

Lung cancer is the leading cause of cancer-related death globally (Bray et al., 2018). Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) offer significant clinical benefit for patients with EGFR mutations (Fukuoka et al., 2011; Zhou et al., 2011). Osimertinib, a third-generation EGFR-TKI, is currently the standard treatment for patients with progression after first- or second- generation EGFR-TKIs because of the T790M mutation or as a first-line treatment for EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC) (Mok et al., 2017; Ramalingam et al., 2018; Soria et al., 2018). Unfortunately, acquired resistance to osimertinib is inevitable (Yang et al., 2018). Thus, innovative treatment strategies are urgently needed to overcome acquired resistance to osimertinib.

Although osimertinib resistance is not fully elucidated, the mechanisms have been divided into EGFR-dependent mechanisms such as EGFR mutations (C797S and L798I) and EGFR-independent mechanisms such as bypass of MET or ErbB2 signaling activation (Oxnard et al., 2018; Yang et al., 2018). Various mechanisms of osimertinib resistance contribute to the difficulty in finding ways to overcome it, and there are no effective strategies currently. Therefore, it is of great importance to investigate new resistance mechanisms as well as strategies to cope with resistance.

Recent studies have shown that the therapeutic efficacy of osimertinib is closely related to the induction of apoptosis. Research involving two osimertinib-resistant cell lines strongly suggests that the critical mechanism by which sensitive EGFR-mutant NSCLC cells become resistant to osimertinib-mediated apoptosis induction occurs via an inability of osimertinib to modulate B-cell lymphoma 2-like 11 (Bim) and myeloid cell leukemia sequence 1 (Mcl-1) levels (Shi et al., 2017). Thus, promoting apoptosis may overcome osimertinib resistance in osimertinib resistant cell lines, and identifying a clinically available drug that induces apoptosis may be a feasible strategy for overcoming osimertinib resistance.

Acetylsalicylic acid (aspirin), one of the most common non-steroidal anti-inflammatory drugs (NSAIDs), is widely used as an antiplatelet agent to prevent myocardial infarction and stroke. Accumulated recent studies have reported the correlation with long-term aspirin application and

---

low risk of cancer mortality (Bradley et al., 2016; Lucotti et al., 2019; Merritt et al., 2018; Simon et al., 2018). What's more, aspirin has been recommended for primary prevention of colorectal cancer (Brenner and Chen, 2018), and can also induce apoptosis in tumor cells, as demonstrated by its ability to act synergistically with erlotinib to induce apoptosis in human EGFR mutant NSCLC cell lines (Hu et al., 2018). Consequently, we postulated aspirin might overcome osimertinib resistance by inducing apoptosis.

In our study, we evaluated whether aspirin in combination with osimertinib has synergistic antitumor activity using various *in vitro* and *in vivo* approaches, including the thiazolyl blue tetrazolium bromide (MTT) assay, flow cytometry, western blot assay and xenografts. Our investigations showed aspirin can sensitize osimertinib resistance NSCLC cells to osimertinib *in vitro* and *in vivo* by inducing apoptosis, which is dependent by inhibition of Akt/FoxO3a signaling component phosphorylation and increased Bim expression. We thereby provide rationale and evidence for considering the use of aspirin in combination with osimertinib to overcome osimertinib resistance in NSCLC patients.

## **Materials and Methods**

### **Cell lines and reagents**

Gefitinib-resistant PC-9GR cells were donated by Prof. J. Xu and Dr. M. Liu from Guangzhou Medical University (China). These cells harbored EGFR 19 Del and T790M mutations and were sensitive to osimertinib. Erlotinib-resistant H1650-M3 cells were kindly provided by Dr. R. Sordella. H1975 cells were obtained from American Type Culture Collection, and these cells harbored EGFR L858R and T790M mutations and were sensitive to osimertinib. All the osimertinib resistant PC-9GROR, H1975-OR cell lines and rociletinib (CO1686) resistant PC-9GRCOR, H1975-COR cell lines were constructed in our laboratory. The corresponding osimertinib parental and resistant cells were first treated with osimertinib at the concentration of IC<sub>50</sub> for 2 weeks. Then were treated with a higher concentration for another 3 weeks sufficient to kill nearly all the parental cells. Finally the remaining resistant clones were seeded single cell per well and were cultured continuously in the presence of osimertinib (Li et al., 2019).

---

Rociletinib(CO1686)-resistant cell lines were established in a manner similar to the osimertinib-resistant cell lines (Pan et al., 2018). Treatment with 200  $\mu\text{mol/L}$  aspirin alone for 48 h slightly decreased the viability of PC-9GR, H1975, H1650-M3, PC-9GROR, H1975-OR, PC-9GRCOR and H1975-COR cells (Fig. S1). Therefore, we chose a combination of 200  $\mu\text{mol/L}$  aspirin and different doses of osimertinib to treat cell lines resistant to third-generation EGFR-TKIs. All the cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 (HyClone) medium supplemented with 10% fetal bovine serum (Gibco), 100 U/mL penicillin (HyClone), and 100  $\mu\text{g/mL}$  streptomycin (HyClone) at 37°C in 5% CO<sub>2</sub> and 90% humidity.

Osimertinib (Tagrisso) was obtained from Astra Zeneca, rociletinib was purchased from Selleck Chemicals, gefitinib (Iressa) was purchased from MedChem Express, erlotinib (Tarceva) was obtained from Cayman Chemical, aspirin (A2093) was purchased from Sigma-Aldrich, and aspirin (S3017) was obtained from Selleck Chemicals. Osimertinib, rociletinib, gefitinib, erlotinib and aspirin were dissolved in DMSO. Human insulin-like growth factor (IGF)-1 (#100-11) was purchased from PeproTech. Antibodies against Bim (#2933S), Mcl-1 (#5453S), p-Mcl-1 (#14765S), B-cell lymphoma 2 (Bcl-2; #2870S), Bcl-2-associated X protein (BAX; #5023S), Akt (#9272S), phospho (Ser473)-Akt (#4060S), FoxO3a (#2497S), phospho-FoxO3a (#9466S), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; #2118S) were obtained from Cell Signaling Technology.

### **Cell proliferation assays**

Cell viability was assessed using MTT assays (Takahashi et al., 2018). Cells were seeded at 2000 cells per well in 96-well plates and incubated in RPMI-1640+10% FBS. MTT assay for parental PC-9GR, H1975 cells and their corresponding osimertinib or rociletinib resistant cells treated with DMSO, indicated doses of osimertinib(1  $\mu\text{mol/L}$  in PC-9GROR cells, 3  $\mu\text{mol/L}$  in H1975-OR cells), osimertinib plus aspirin(200  $\mu\text{mol/L}$ ) or rociletinib(0.5  $\mu\text{mol/L}$  in PC-9GROR cells, 3  $\mu\text{mol/L}$  in H1975-OR cells), rociletinib plus aspirin for 48 h. Experiments were performed in triplicate, and data are mean  $\pm$  SEM.

### **Apoptosis assessment**

Apoptosis was detected using flow cytometry analysis and the terminal deoxynucleotidyl

---

transferase dUTP nick end labeling (TUNEL) staining assay. Cells were collected by trypsinization at 48 h after different treatments, washed three times with phosphate-buffered saline (PBS), and resuspended at a density of  $1 \times 10^6$  cells/ml. After double staining with PI for 30 min at ambient temperature in the dark using FITC Annexin V Apoptosis Detection Kit I, the cells were analyzed using a flow cytometer (Beckman Coulter Novios, FL, USA).

### **Reverse transcription-polymerase chain reaction (RT-PCR)**

Total cellular RNA was extracted from the cells using TRIzol reagent (#15596026, Thermo Scientific, USA) and reverse transcribed using an iScript gDNA clear cDNA Synthesis Kit (Bio-Rad, USA). The mRNA expression was amplified by 5× Pfu PCR MasterMix using a CFX96 Touch System (Bio-Rad, USA). The forward and reverse primers for human Bim were 5'-CCACCAATGGAAAAGGTTCA-3' and 5'-GGCACAGCCTCTATGGAGAA-3', respectively, and the forward and reverse primers for human GAPDH were 5'-GGTGAAGGTCGGAGTCAACG-3' and 5'-CAAAGTTGTCATGGATGACC-3', respectively. Amplified fragments in DNA loading buffer were subjected to agarose gel electrophoresis for 40 min at 110 V, followed by labeling with GoldView staining solution and visualization using the ChemiDoc Touch System (Bio-Rad, USA).

### **Western blot analysis**

Cells were scraped from culture vessels and washed twice with PBS. The cells were then lysed for 30 min at 4°C in radio-immunoprecipitation assay buffer (Sigma-Aldrich, USA). The cellular debris was removed by centrifugation at  $12,000 \times g$  for 30 min at 4°C, and the protein concentration was determined using the Bradford method (Millipore, Germany). Equal amounts of protein were subjected to gel electrophoresis for 2 h at 110 V, followed with which were transferred into polyvinylidene difluoride membranes (90 min, 200 mA) (Millipore, Germany). Then the membranes were blocked with 5% bovine serum albumin for 1 h at room temperature and incubated overnight at 4°C with primary antibodies. Subsequently, the membranes were washed and incubated with 0.02 µg/mL horseradish peroxidase-conjugated goat anti-rabbit (Cell Signaling Technology, USA) for 1 h, followed by visualization with ChemiDoc Touch System (Bio-Rad, USA).

---

### **Xenograft studies**

All animal protocols were approved by the Ethics Committee of Army Medical University. Four-week-old female BALB/c A-nu mice (Laboratory Animal Center of Army Medical University, Chongqing, China) were injected subcutaneously into the back (next to the left forelimb) with  $2 \times 10^6$  PC-9GROR cells. Once the tumors reached a size of approximately 50 mm<sup>3</sup> (within 5 to 7 days), the mice were randomly assigned to one of four groups (5 mice/group). Based on other prior studies, the mice were given osimertinib (5 mg/kg), aspirin (20 mg/kg), and a combination of osimertinib and aspirin by means of intragastric administration (Chen et al., 2018; Shi et al., 2017). The tumor volume was calculated as  $(\text{length} \times \text{width}^2)/2$  and measured twice per week. The mice were maintained in individual ventilated cages in compliance with institutional guidelines. They were monitored for 5 weeks until euthanasia. For western blot analysis, the tumors were homogenized in protein lysis buffer. To assess survival, once the tumors reached a size of approximately 50 mm<sup>3</sup>, the animals were randomly assigned to one of three groups (10 mice/group) and treated with intragastric administration once daily with water alone or water containing osimertinib (5 mg/kg) or a combination of osimertinib and aspirin. The mice were monitored for 100 days until they were euthanized.

### **Patient information**

This study was approved by the Institutional Review Board of Daping Hospital, Army Military Medical University. All patients provided informed consent for this study and gave permission to the entire study. Disease progression was confirmed in each patient according to the RECIST 1.1 criteria. Clinical information was retrospectively obtained from 45 patients presenting with NSCLC who had received first-generation EGFR-TKI (gefitinib or erlotinib) therapy and were resistant due to T790M mutation. Then, the patients had received osimertinib therapy in Daping Hospital between January 2015 and January 2019. These patients were histologically or cytologically confirmed to harbor either exon 19 deletion or L858R mutation and T790M mutation. All participants provided written consent before enrollment. This study was approved by the Ethics Committees of the Daping Hospital, Army Medical University, and conformed to the tenets of the Declaration of Helsinki.

---

## Statistical analysis

All data were analyzed using Student's t-test, and the results are expressed as the mean  $\pm$  SEM of triplicate samples. Survival percentages over time were estimated using the Kaplan-Meier method. Statistical significance was assumed at an alpha value of  $p < 0.05$ .

## Results

### Aspirin sensitizes osimertinib-resistant NSCLC patients to osimertinib

We incidentally observed osimertinib sensitization in two patients with advanced NSCLC. The two *EGFR*-positive advanced lung adenocarcinoma never smoker female patients (58 years old, T4N2M1, L858R; 61 years old, T2N3M1, 19Del) were administered gefitinib and subsequent osimertinib. Both patients were received 80 mg osimertinib once daily and achieved partial response (PR), with a progression-free survival (PFS) of 26.5 months or 28 months, respectively. Due to the retention of *EGFR* T790M and no other resistance mechanism was detected at disease progression, these patients remained on osimertinib. In addition, they both experienced cardiovascular disease, and 100 mg aspirin daily was coadministered with osimertinib. The addition of aspirin effectively reversed osimertinib resistance and resulted in a significant reduction in the size of the primary lesion, achieving the best response of PR, with a PFS of 7 months (Fig. 1A and Fig. S2). The two case prompt that aspirin and osimertinib may have synergistic antitumor activity.

### Aspirin sensitizes osimertinib in osimertinib-resistant NSCLC cell lines

To detect the effects of aspirin *in vitro*, we used the osimertinib resistant NSCLC PC-9GROR and H1975-OR cells, which are highly resistant to osimertinib (Li et al., 2019). Next-generation sequencing showed the presence of an *EGFR*-sensitive mutation (Del19 or L858R) and the T790M mutation in both NSCLC cell lines; however, *MET* amplification was detected only in the H1975-OR cell line (Fig. 1B). The MTT assay showed that PC-9GR and H1975 cells are sensitive to osimertinib whereas that PC-9GROR and H1975-OR cells are highly resistant to osimertinib. Treatment with 200  $\mu$ mol/L aspirin resensitized PC-9GROR cells and H1975-OR cells to osimertinib (Fig. 1C and Fig. S3A). Moreover, treatment with 200  $\mu$ mol/L aspirin

---

resensitized PC-9GRCOR and H1975-COR cells to the other third-generation EGFR-TKI rociletinib (Fig. 1C and Fig. S3B). We also found that aspirin was able to resensitize the first-generation EGFR-TKIs gefitinib and erlotinib (Fig. S3C and Fig. S3D). The results from both colony formation and Ki67 assays confirmed enhanced inhibitory effects of aspirin plus osimertinib in PC-9GROR and H1975-OR cells (Fig. 1D and Fig. 1E). Taken together, these results indicate that aspirin can resensitize osimertinib to osimertinib-resistant NSCLC cell lines.

### **Reduced apoptosis leads to osimertinib resistance in EGFR mutant NSCLC cell lines**

Reduced apoptosis has been previously demonstrated as an important factor associated with osimertinib resistance (Shi et al., 2017). First, we observed that osimertinib-resistant cells (PC-9GROR and H1975-OR) displayed morphologic features similar to those of parental cells (Fig. S4A). As shown in Fig. 2A, flow cytometry revealed that osimertinib and rociletinib increased the percentage of annexin V-positive PC-9GR and H1975 cells. However, treatment with osimertinib or rociletinib produced a dramatic decline in the percentage of annexin V-positive PC-9GROR, H1975-OR, PC-9GRCOR and H1975-COR cells. Similar results in PC-9GROR and H1975-OR cells were obtained using the TUNEL assay (Fig. 2B). With osimertinib treatment, there were clearly more apoptotic PC-9GR and H1975 cells than PC-9GROR and H1975-OR cells. Moreover, western blot analysis showed that osimertinib significantly increased expression of the apoptosis-related protein Bim and decreased that of Mcl-1 and Bcl-2 in PC-9GR and H1975 cells, though osimertinib only slightly increased Bim and decreased Mcl-1 and Bcl-2 in PC-9GROR and H1975-OR cells. Similar results were observed in the rociletinib-resistant cell lines PC-9GRCOR and H1975-COR. In contrast, BAX was unchanged by osimertinib treatment in all cell lines (Fig. 2C).

Together, these results indicate that apoptosis is reduced in our osimertinib resistant NSCLC cell lines and that osimertinib cannot induce changes to apoptosis-related proteins in these cells. Thus, a reduced ability to induce apoptosis is associated with acquired resistance to osimertinib.

### **Aspirin induces apoptosis in osimertinib-resistant NSCLC cell lines**

We next examined whether aspirin can increase the antiproliferative effects of osimertinib by inducing apoptosis. We first observed cell morphology and noted no obvious changes after

---

treatment with aspirin or osimertinib alone (Fig. S4B). Flow cytometry showed that although osimertinib or aspirin treatment alone had little effect on apoptosis in either PC-9GROR or H1975-OR cells, combining the two drugs significantly enhanced this process in both cell lines, indicating that aspirin further augments the apoptotic effects of osimertinib. Similar phenomenon was also observed in rociletinib resistant cell lines when combined treated with aspirin and rociletinib (Fig. 3A). Moreover, TUNEL assay further revealed that the apoptotic PC-9GROR and H1975-OR cells were clearly enhanced after exposure to osimertinib and aspirin concurred treatment (Fig. 3B).

According to western blot analysis, aspirin clearly increased Bim expression in both PC-9GROR and H1975-OR cells, and the combination of aspirin and osimertinib produced sustained Bim elevation in both cell lines, though Mcl-1 degradation was obvious only in PC-9GROR cells (Fig. 3C). Bcl-2 and BAX levels did not differ significantly following treatment of PC-9GROR or H1975-OR cells with aspirin plus osimertinib. However, both Bim elevation and p-Mcl-1 suppression were observed in the rociletinib-resistant cell lines PC-9GRCOR or H1975-COR. These findings suggest that Bim elevation may be a common mechanism through which aspirin overcomes osimertinib and rociletinib resistance by blocking proliferation and/or inducing apoptosis in PC-9GROR and H1975-OR cells. In gefitinib-resistant and erlotinib-resistant cell lines, aspirin also overcome resistance by increasing Bim (Fig S5A-B).

**Bim-dependent apoptosis is an important mechanism underlying aspirin's ability to re-sensitize osimertinib in NSCLC cell lines**

To further confirm the essential role of Bim elevation in mediating aspirin-induced apoptosis, we first used western blot analyses to detect Bim expression in PC-9GROR and H1975-OR cells treated with aspirin for different durations or at different doses. In both cell lines, Bim expression gradually increased in a time-dependent manner when aspirin was administered for 0 to 72 h and in a dose-dependent manner when aspirin doses ranged from 0 to 250  $\mu\text{mol/L}$  (Fig. 4A and Fig. S6A-B). Subsequently, we used Bim siRNAs to knock down Bim expression in PC-9GROR and H1975-OR cells and examined the impact on synergistic growth inhibition by aspirin and osimertinib. As Bim siRNA#2 knocked down Bim expression in both PC-9GROR and H1975-OR

---

cells, as confirmed by western blot analyses (Fig. 4B), we used Bim siRNA#2 to treat PC-9GROR and H1975-OR cells for 48 h. MTT assays showed that Bim knockdown partially weakened the synergistic effects of aspirin and osimertinib in inhibiting cell proliferation (Fig. 4C). Similarly, the proliferative cells detected by Ki67 assay after knocking down Bim in PC-9GROR and H1975-OR cells present no significant difference in combined group than either agent alone (Fig. 4D and Fig. S7A). Whereas when the cells were transfected with Bim siRNA#2, Flow cytometry analysis showed the combination of aspirin and osimertinib obviously decrease apoptosis than either agent alone (Fig. 4E and Fig. S7B). Taken together, these results suggest that Bim elevation is an important mechanism underlying the ability of aspirin to re-sensitize osimertinib by inducing apoptosis in osimertinib-resistant cells.

#### **Aspirin enhances Bim expression by inhibiting Akt-FoxO3a signaling in osimertinib-resistant NSCLC cell lines**

As Bim is a critical apoptosis regulatory protein and is strictly mediated by both transcription pattern and post-translational modification pattern, to better clarify the subtle mechanism of Bim elevation caused by aspirin, we performed RT-PCR assay in PC-9GROR and H1975-OR cells first. According to the RT-PCR data, Bim mRNA level was significantly enhanced after aspirin concurrent treatment with osimertinib, comparing with aspirin or osimertinib individual treatment, illustrating Bim elevation was modulated by aspirin transcriptionally (Fig 5A).

Then, we detected the key signaling pathways for Bim transcription regulation. We used western blotting to analyze Akt and Erk phosphorylation in PC-9GROR and H1975-OR cells treated for 48 h with aspirin, osimertinib, or both (Petigny-Lechartier et al., 2017; Wu et al., 2016). Erk phosphorylation was strongly inhibited by the combination of aspirin and osimertinib in PC-9GROR cells but not in H1975-OR cells. In contrast, Akt phosphorylation was strongly inhibited by the combination treatment in both cell lines (Fig. 5B). Similar results were observed in PC-9GR, H1975, PC-9GRCOR, H1975-COR and H1650-M3 cells (Fig. S8A-C). These results suggest that inhibition of Akt phosphorylation is a common molecular mechanism by which aspirin elevates Bim expression, regardless of the genetic background of the osimertinib-resistant cells.

---

Previous studies have reported that Akt/FoxO3a signaling modulates Bim transcription, suggesting that FoxO3a phosphorylation may play a prominent role in regulating Bim protein synthesis (Yue and Sun, 2018). Western blot analysis showed that aspirin decreased FoxO3a phosphorylation in the presence of osimertinib (Fig. 5C). In addition, immunofluorescence staining indicated that FoxO3a is transferred from the cytoplasm to the nucleus during aspirin treatment and that FoxO3a assembly in the nucleus activates Bim protein synthesis (Fig. 5D). Next, to examine the effects of Akt phosphorylation during aspirin, osimertinib, or combination treatment, we administered IGF-1 (an Akt activator) to PC-9GROR and H1975-OR cells and found that FoxO3a phosphorylation was increased but Bim expression decreased following combinatory treatment (Fig. S9). MTT assay results showed that IGF-1 partially weakened the synergistic effects of aspirin and osimertinib in inhibiting PC-9GROR and H1975-OR cell proliferation (Fig. 5E). In summary, the results suggest that aspirin combined with osimertinib modulates Bim expression by inhibiting Akt and FoxO3a phosphorylation.

#### **The combination of aspirin and osimertinib inhibits the growth of osimertinib-resistant NSCLC xenografts in nude mice**

Based on the above findings, we evaluated whether the combination of aspirin and osimertinib is effective in xenografts established from PC-9GROR cells. Compared with untreated control mice, mice treated with aspirin or osimertinib alone presented a slightly reduced rate of xenograft tumor growth. Importantly, compared with treatment with either agent alone, treatment with the combination of aspirin and osimertinib significantly reduced tumor growth (Fig. 6A and Fig. 6B). After 5 weeks of drug administration (when the animals were sacrificed), the mean tumor weight in mice bearing PC-9GROR tumor xenografts treated with aspirin or osimertinib alone was less than that in the control group. Tumor weight was significantly lower following treatment with a combination of aspirin and osimertinib than in all other groups (Fig. 6C). Furthermore, the log-rank test showed that compared with mice treated with osimertinib alone or those in the control group, mice treated with osimertinib plus aspirin presented significantly prolonged survival (Fig. 6D). No obvious weight loss was observed in any of the mice, including those treated with aspirin plus osimertinib (Fig. S10).

---

Western blotting was applied to detect protein expression in PC-9GROR xenografts, and the results showed that phosphorylation of Akt and FoxO3a was strongly inhibited and that Bim expression was significantly elevated in mice treated with the combination compared with mice treated with aspirin or osimertinib alone (Fig. 6E). Collectively, these results indicate that osimertinib plus aspirin significantly slows tumor growth, prolongs survival and may overcome osimertinib resistance in vivo by inhibiting Akt/FoxO3a signaling phosphorylation and increasing Bim expression.

### **Clinical evidence of combinatorial therapy with osimertinib with aspirin**

The retrospective analysis included 45 NSCLC patients with a median age of 59 years (range, 38-84 years). Of these patients, 27 harbored EGFR 19Del and 18 L858R (Table S1). All patients exhibited resistance to a first-generation EGFR-TKI (gefitinib or erlotinib) due to the T790M mutation and had received osimertinib treatment. Moreover, 14 patients received osimertinib while taking aspirin due to cardiovascular disease or thrombus, and 31 other patients received osimertinib alone. As shown in table S1, there were no significant differences in age, sex or EGFR mutation status between the two groups. Among the 45 patients, 36 (80%) experienced a reduction in measurable tumor size (Fig. 6F). The median PFS was 15.3 months and 9.3 months for patients in the osimertinib plus aspirin group and osimertinib group, respectively. The median PFS in the osimertinib plus aspirin group was significantly longer than that in the osimertinib group ( $p=0.023$ ) (Fig. 6G). We also compared the therapeutic effect of osimertinib on 19Del and L858R mutations, though the difference was not statistically significant in either group (osimertinib plus aspirin group:  $p=0.487$ , osimertinib group:  $p=0.697$ ) (Table S1).

## **Discussion**

Patient-reported outcomes from FLAURA: among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received gefitinib or erlotinib (38.6 vs 31.8 months) (Ramalingam et al., 2020). Unfortunately, the acquired resistance to osimertinib is inevitable, the molecular mechanism underlying acquired osimertinib resistance was still not fully elucidated (Le et al.,

---

2018), and therapeutic strategies for osimertinib resistance are limited. Previous studies have employed the combination of a first-generation EGFR-TKI with osimertinib if the C797S and T790M mutations occurred in cis (Niederst et al., 2015) and the combination of crizotinib with osimertinib if MET amplification was present (Deng et al., 2018). Combination treatment with MEK/BRAF-V600E inhibitors is another therapeutic strategy to overcome osimertinib resistance (Ho et al., 2017; Shi et al., 2017). These previous studies demonstrate that the use of drug combinations may be a highly effective approach for overcoming osimertinib resistance. In this study, we found that aspirin overcome drug resistance to osimertinib in NSCLC cell lines and that combining aspirin with osimertinib significantly decreased the growth of NSCLC tumor xenografts in vivo and prolonged the survival of mice with these tumors. Accordingly, aspirin may be a clinically feasible drug for overcoming osimertinib resistance.

There has been extensive interest in aspirin as a potential anticancer agent since the publication of clinical reports indicating that the NSAID reduces cancer risk and mortality in colon cancer, hepatocellular cancer, and other cancers (Ait Ouakrim et al., 2015; Lin et al., 2018; Simon et al., 2018; Wield et al., 2018). Further evidence suggests that aspirin exerts remarkable antitumor properties in various tumor cells, including lung cancer cells (Khan et al., 2016), and in mouse models (Henry et al., 2017; Liao et al., 2015; Navone et al., 2018). Previous studies have shown that combining aspirin with erlotinib enhanced the effects of erlotinib in killing EGFR-mutant NSCLC cells (Hu et al., 2018; Song et al., 2018) and that combining aspirin with sorafenib and other drugs significantly suppressed cancer growth and prolonged remission in xenograft models (Amaral et al., 2018; Miao et al., 2018; Xia et al., 2017; Zhang et al., 2017). Our current study likewise demonstrated that concomitant treatment with aspirin can overcome osimertinib resistance. Furthermore, we observed that aspirin can overcome resistance to another third-generation EGFR-TKI, rociletinib, and the first-generation EGFR-TKIs gefitinib and erlotinib, as reported in another paper (Hu et al., 2018). Together, our results and those of other studies suggest that combining aspirin with osimertinib is a promising new strategy for overcoming osimertinib resistance and improving the survival of patients with NSCLC.

The specific molecular mechanisms by which aspirin overcomes osimertinib resistance have

---

not been fully elucidated. Reduced apoptosis is associated with the development of drug resistance (Chen et al., 2017; Li et al., 2014; Yochum et al., 2018), and in the current study, osimertinib induced apoptosis in EGFR-mutant NSCLC cell lines but not in osimertinib resistant NSCLC cells. These findings are consistent with the results of previous studies (Shi et al., 2017). Furthermore, apoptosis induction has been demonstrated to enhance the effectiveness of TKIs and chemotherapy drugs in inhibiting tumor cell growth (Morgillo et al., 2013; Shukla et al., 2017). Our current results clearly demonstrate that apoptosis induction is a viable strategy for overcoming osimertinib resistance. Bim, a member of the BCL-2 family of proteins, is a critical modulator of apoptosis (Kang and Reynolds, 2009; Ng et al., 2012). We found that aspirin increased Bim levels in osimertinib resistant NSCLC cells; additionally, when Bim expression was knocked down by Bim siRNA, the synergistic effects of aspirin and osimertinib were greatly reduced. Therefore, the ability of aspirin to overcome osimertinib resistance by inducing apoptosis is possibly mediated by increased Bim expression.

Regarding the mechanism by which aspirin modulates Bim expression in osimertinib-resistant NSCLC cells, previous studies report that Bim induction is a consequence of both posttranslational modification and transcriptional induction, which depend on Akt and the Erk signaling pathway (Petigny-Lechartier et al., 2017; Wu et al., 2016). A recent study reported that the transcription factor FoxO3a regulates Bim expression in response to many stimuli (Essafi et al., 2005). FoxO3a can also activate the Bim gene directly, disrupt mitochondrial integrity, release cytochrome C, promote activation of apoptotic proteins such as caspase-3, and induce apoptosis in tumor cells (Gilley et al., 2003). In the current study, we observed that dephosphorylated FoxO3a enters the nucleus, where it binds directly to the conserved FoxO-binding element in the promoter of the Bim gene to induce apoptosis (Vogiatzi et al., 2006). The basal levels of the FoxO3a and Bim proteins (which were already high), as well as Bim mRNA, were increased dramatically after aspirin treatment, and this increase was associated with induction of apoptosis in osimertinib-resistant NSCLC cells. In addition, previous evidence indicates that phosphorylated Akt or Erk phosphorylates FoxO3a and block FoxO3a nuclear entry. We demonstrated that inhibition of Akt phosphorylation can induce apoptosis (and thereby

---

overcome osimertinib resistance) in both PC-9GROR and H1975-OR cell lines through dephosphorylated FoxO3a and elevated Bim levels; however, inhibition of Erk phosphorylation by aspirin was just observed in PC-9GROR cells whereas not in H1975-OR cells. These results indicate that the aspirin-mediated increase in Bim expression in PC-9GROR and H1975-OR cells was not Erk dependent, a result that differs from that reported by Sun et al. (Shi et al., 2017). This finding suggests that other common mechanisms such as Akt/FoxO3a signaling, may be involved in the effects of aspirin. Therefore, we postulate that aspirin acts by inhibiting phosphorylation of Akt/FoxO3a signaling components and promoting FoxO3a transfer to the nucleus to increase Bim expression and induce tumor cell apoptosis. Moreover, a retrospective analysis was performed in 45 NSCLC patients with acquired resistance to first-generation EGFR-TKIs who were administered with osimertinib as the secondline treatment. The results of this analysis also showed that aspirin can postpone osimertinib resistance. Interestingly, anti-tumor effects of aspirin was closely correlated with PGE2 reduction (Ma et al., 2017). Therefore, to investigate the probable way aspirin mediating osimertinib resistance, ELISA assay was performed to observe the PGE2 secretion in osimertinib parental and resistant cells with ELISA kits. Regretfully, there was no significant difference in the level of PGE2 between osimertinib resistant and parental cell lines (Fig. S11).

Herein, we describe for the first time the beneficial effects of combined treatment with osimertinib and aspirin in patients with osimertinib resistance and present experimental in vitro and in vivo data to support and explain this conclusion (Fig. S 12). Based on other prior studies, the dosage of aspirin, which was given by oral gavage, used in the in vivo study (20 mg/kg/day) corresponds to a dose of 60 mg/m<sup>2</sup> in humans, which is equivalent to a clinical dose of 100 mg for the average body surface area or approximately one aspirin tablet taken for the purposes of decreasing risk factors for cardiovascular disease in 50-kg humans. The dose of aspirin used in their vitro study (200 μmol/L) is in accordance with the IC<sub>25</sub> in NSCLC cells observed in this study and much lower than that used in most reports (Chen et al., 2018; Hossain et al., 2012; Stark et al., 2007). We have developed three clinical trials, which are registered at ClinicalTrials.gov (NST: 03543683, NST: 03532698 and NST: 04184921), to observe whether aspirin combination

---

with osimertinib could delay the appearance of resistance to osimertinib and the clinical benefits of aspirin combined with osimertinib in treating patients with acquired resistance to first-generation EGFR-TKIs or osimertinib. These trials aim to provide solid clinical evidence to further the development of aspirin plus osimertinib as a new combination therapeutic strategy for overcoming acquired osimertinib resistance and prolonging survival in patients with NSCLC.

### **Conclusions**

In summary, this study demonstrates that the combination of aspirin and osimertinib can overcome osimertinib resistance *in vitro* and *in vivo*. Aspirin, an “old drug”, has been used as an analgesic anti-inflammatory medication for more than a century and is known for its safety, reliability, and low cost. We have now discovered that aspirin plays a crucial role in overcoming osimertinib resistance by inhibiting phosphorylation of Akt/FoxO3a signaling components and up-regulating Bim protein synthesis in osimertinib-resistant EGFR-mutated NSCLC cells. Modulating Bim transcription may not be the only mechanism by which aspirin overcomes osimertinib resistance in EGFR-mutated NSCLC, and in-depth clinical studies will continue to identify other potential markers linked to aspirin’s beneficial effects. Based on our findings, we suggest that combining aspirin with osimertinib may be an effective and economical therapeutic strategy for overcoming acquired osimertinib resistance.

---

## Acknowledgments

We thank Dr. Raffaella Sordella from Cold Spring Harbor Laboratory for kindly providing the valuable cell lines used in the current study. We would also like to thank Dr. Lei Ai from Tongshu Gene Co. Ltd and Dr. Hanqing Lin from Origimed Co. Ltd for data analysis and Dr. Xuefeng Xia from Gene+ Co. Ltd for editing the manuscript.

**Data accessibility:** No data deposited in public database or repository

**Competing interests:** No potential conflicts of interest are disclosed.

**Funding:** This work was supported by the Natural Science Foundation of China (81802293, 81672284, 81702291 and 81902343).

## Authors' contributions

YH conceived and designed the project. RH directly supervised the study, designed experiments and wrote the paper. RH, SH, CHL and CZ acquired the data. CL, CH and YBW participated in discussion of the project. YH and LL directly supervised the study.

## REFERENCES

- Ait Ouakrim, D., Dashti, S.G., Chau, R., Buchanan, D.D., Clendenning, M., Rosty, C., Winship, I.M., Young, J.P., Giles, G.G., Leggett, B., Macrae, F.A., Ahnen, D.J., Casey, G., Gallinger, S., Haile, R.W., Le Marchand, L., Thibodeau, S.N., Lindor, N.M., Newcomb, P.A., Potter, J.D., Baron, J.A., Hopper, J.L., Jenkins, M.A., Win, A.K., 2015. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. *Journal of the National Cancer Institute* 107.
- Amaral, M.E.A., Nery, L.R., Leite, C.E., de Azevedo Junior, W.F., Campos, M.M., 2018. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. *Investigational new drugs* 36, 782-796.
- Bradley, M.C., Black, A., Freedman, A.N., Barron, T.I., 2016. Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Cancer* 122, 2067-2075.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for*

---

clinicians 68, 394-424.

Brenner, H., Chen, C., 2018. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *British journal of cancer* 119,785-792.

Chen, H., Wang, Y., Lin, C., Lu, C., Han, R., Jiao, L., Li, L., He, Y., 2017. Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction. *Oncotarget* 8, 93825-93838.

Chen, Z., Li, W., Qiu, F., Huang, Q., Jiang, Z., Ye, J., Cheng, P., Low, C., Guo, Y., Yi, X., Chen, W., Yu, Y., Han, Y., Wu, J., Jin, S., Kong, D., Huang, J., 2018. Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer. *Theranostics* 8, 4447-4461.

Deng, L., Kiedrowski, L.A., Ravera, E., Cheng, H., Halmos, B., 2018. Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 13, e169-e172.

Essafi, A., Fernandez de Mattos, S., Hassen, Y.A., Soeiro, I., Mufti, G.J., Thomas, N.S., Medema, R.H., Lam, E.W., 2005. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. *Oncogene* 24, 2317-2329.

Fukuoka, M., Wu, Y.L., Thongprasert, S., Sunpaweravong, P., Leong, S.S., Sriuranpong, V., Chao, T.Y., Nakagawa, K., Chu, D.T., Saijo, N., Duffield, E.L., Rukazenzov, Y., Speake, G., Jiang, H., Armour, A.A., To, K.F., Yang, J.C., Mok, T.S., 2011. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 29, 2866-2874.

Gilley, J., Coffey, P.J., Ham, J., 2003. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. *The Journal of cell biology* 162, 613-622.

Henry, W.S., Laszewski, T., Tsang, T., Beca, F., Beck, A.H., McAllister, S.S., Toker, A., 2017. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. *Cancer research* 77, 790-801.

Ho, C.C., Liao, W.Y., Lin, C.A., Shih, J.Y., Yu, C.J., Chih-Hsin Yang, J., 2017. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 12, 567-572.

Hossain, M.A., Kim, D.H., Jang, J.Y., Kang, Y.J., Yoon, J.H., Moon, J.O., Chung, H.Y., Kim, G.Y., Choi, Y.H., Cople, B.L.,

---

Kim, N.D., 2012. Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. *International journal of oncology* 40, 1298-1304.

Hu, X., Wu, L.W., Weng, X., Lin, N.M., Zhang, C., 2018. Synergistic antitumor activity of aspirin and erlotinib: Inhibition of p38 enhanced aspirin plus erlotinib-induced suppression of metastasis and promoted cancer cell apoptosis. *Oncology letters* 16, 2715-2724.

Kang, M.H., Reynolds, C.P., 2009. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research* 15, 1126-1132.

Khan, P., Manna, A., Saha, S., Mohanty, S., Mukherjee, S., Mazumdar, M., Guha, D., Das, T., 2016. Aspirin inhibits epithelial-to-mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug. *BMC cancer* 16, 39.

Le, X., Puri, S., Negrao, M.V., Nilsson, M., Robichaux, J.P., Boyle, T.A., Hicks, J.K., Lovinger, K., Roarty, E.B., Rinsurongkawong, W., Tang, M., Sun, H., Elamin, Y.Y., Lacerda, L., Lewis, J., Lee, J.J., Roth, J.A., Swisher, S.G., Zhang, J., William, W.N., Glisson, B.S., Papadimitrakopoulou, V.A., Gray, J.E., Heymach, J.V., 2018. Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research* 24, 6195-6203.

Li, L., Han, R., Xiao, H., Lin, C., Wang, Y., Liu, H., Li, K., Chen, H., Sun, F., Yang, Z., Jiang, J., He, Y., 2014. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. *Clinical cancer research : an official journal of the American Association for Cancer Research* 20, 2714-2726.

Li, L., Wang, Y., Jiao, L., Lin, C., Lu, C., Zhang, K., Hu, C., Ye, J., Zhang, D., Wu, H., Feng, M., He, Y., 2019. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. *Cancer letters* 452, 191-202.

Liao, D., Zhong, L., Duan, T., Zhang, R.H., Wang, X., Wang, G., Hu, K., Lv, X., Kang, T., 2015. Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-kappaB Pathway. *Clinical cancer research : an official journal of the American Association for Cancer Research* 21, 5349-5359.

Lin, Y.S., Yeh, C.C., Huang, S.F., Chou, Y.S., Kuo, L.T., Sung, F.C., Muo, C.H., Su, C.T., Su, F.H., 2018. Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer: A population-based analysis. *PloS one* 13, e0199014.

---

Lucotti, S., Cerutti, C., Soyer, M., Gil-Bernabe, A.M., Gomes, A.L., Allen, P.D., Smart, S., Markelc, B., Watson, K., Armstrong, P.C., Mitchell, J.A., Warner, T.D., Ridley, A.J., Muschel, R.J., 2019. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. *The Journal of clinical investigation* 130, 1845-1862.

Ma, J., Cai, Z., Wei, H., Liu, X., Zhao, Q., Zhang, T., 2017. The anti-tumor effect of aspirin: What we know and what we expect. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 95, 656-661.

Merritt, M.A., Rice, M.S., Barnard, M.E., Hankinson, S.E., Matulonis, U.A., Poole, E.M., Tworoger, S.S., 2018. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. *The Lancet. Oncology* 19, 1107-1116.

Miao, R., Xu, X., Wang, Z., Liu, S., Qu, K., Chen, W., Liu, C., 2018. Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway. *Molecular medicine reports* 17, 3735-3743.

Mok, T.S., Wu, Y.L., Ahn, M.J., Garassino, M.C., Kim, H.R., Ramalingam, S.S., Shepherd, F.A., He, Y., Akamatsu, H., Theelen, W.S., Lee, C.K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., Papadimitrakopoulou, V.A., Investigators, A., 2017. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *The New England journal of medicine* 376, 629-640.

Morgillo, F., Sasso, F.C., Della Corte, C.M., Vitagliano, D., D'Aiuto, E., Troiani, T., Martinelli, E., De Vita, F., Orditura, M., De Palma, R., Ciardiello, F., 2013. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. *Clinical cancer research : an official journal of the American Association for Cancer Research* 19, 3508-3519.

Navone, S.E., Guarnaccia, L., Cordiglieri, C., Crisa, F.M., Caroli, M., Locatelli, M., Schisano, L., Rampini, P., Miozzo, M., La Verde, N., Riboni, L., Campanella, R., Marfia, G., 2018. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling. *World neurosurgery* 120,e380-e391.

Ng, K.P., Hillmer, A.M., Chuah, C.T., Juan, W.C., Ko, T.K., Teo, A.S., Ariyaratne, P.N., Takahashi, N., Sawada, K., Fei, Y., Soh, S., Lee, W.H., Huang, J.W., Allen, J.C., Jr., Woo, X.Y., Nagarajan, N., Kumar, V., Thalamuthu, A., Poh, W.T., Ang, A.L., Mya, H.T., How, G.F., Yang, L.Y., Koh, L.P., Chowbay, B., Chang, C.T., Nadarajan, V.S., Chng, W.J., Than, H., Lim, L.C., Goh, Y.T., Zhang, S., Poh, D., Tan, P., Seet, J.E., Ang, M.K., Chau, N.M., Ng, Q.S., Tan, D.S., Soda, M., Isobe, K.,

---

Nothen, M.M., Wong, T.Y., Shahab, A., Ruan, X., Cacheux-Rataboul, V., Sung, W.K., Tan, E.H., Yatabe, Y., Mano, H., Soo, R.A., Chin, T.M., Lim, W.T., Ruan, Y., Ong, S.T., 2012. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. *Nature medicine* 18, 521-528.

Niederst, M.J., Hu, H., Mulvey, H.E., Lockerman, E.L., Garcia, A.R., Piotrowska, Z., Sequist, L.V., Engelman, J.A., 2015. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. *Clinical cancer research : an official journal of the American Association for Cancer Research* 21, 3924-3933.

Oxnard, G.R., Hu, Y., Mileham, K.F., Husain, H., Costa, D.B., Tracy, P., Feeney, N., Sholl, L.M., Dahlberg, S.E., Redig, A.J., Kwiatkowski, D.J., Rabin, M.S., Paweletz, C.P., Thress, K.S., Janne, P.A., 2018. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. *JAMA oncology* 4, 1527-1534.

Pan, Y.H., Lin, C.Y., Lu, C.H., Li, L., Wang, Y.B., Chen, H.Y., He, Y., 2018. Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-kappaB signaling. *The clinical respiratory journal* 12, 2642-2652.

Petigny-Lechartier, C., Duboc, C., Jebahi, A., Louis, M.H., Abeillard, E., Denoyelle, C., Gauduchon, P., Poulain, L., Villedieu, M., 2017. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737. *Molecular cancer therapeutics* 16, 102-115.

Ramalingam, S.S., Vansteenkiste, J., Planchard, D., Cho, B.C., Gray, J.E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K.H., Cheema, P., Tiseo, M., John, T., Lin, M.C., Imamura, F., Kurata, T., Todd, A., Hodge, R., Saggese, M., Rukazenzov, Y., Soria, J.C., Investigators, F., 2020. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *The New England journal of medicine* 382, 41-50.

Ramalingam, S.S., Yang, J.C., Lee, C.K., Kurata, T., Kim, D.W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenzov, Y., Ghiorghiu, S., Stetson, D., Markovets, A., Barrett, J.C., Thress, K.S., Janne, P.A., 2018. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 36, 841-849.

Shi, P., Oh, Y.T., Deng, L., Zhang, G., Qian, G., Zhang, S., Ren, H., Wu, G., Legendre, B., Jr., Anderson, E., Ramalingam, S.S., Owonikoko, T.K., Chen, M., Sun, S.Y., 2017. Overcoming Acquired Resistance to AZD9291, A Third-Generation

---

EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. *Clinical cancer research* : an official journal of the American Association for Cancer Research 23, 6567-6579.

Shukla, S., Saxena, S., Singh, B.K., Kakkar, P., 2017. BH3-only protein BIM: An emerging target in chemotherapy. *European journal of cell biology* 96, 728-738.

Simon, T.G., Ma, Y., Ludvigsson, J.F., Chong, D.Q., Giovannucci, E.L., Fuchs, C.S., Meyerhardt, J.A., Corey, K.E., Chung, R.T., Zhang, X., Chan, A.T., 2018. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. *JAMA oncology* 4, 1683-1690.

Song, J.M., Upadhyaya, P., Kassie, F., 2018. Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway. *Carcinogenesis* 39, 911-920.

Soria, J.C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K.H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B.C., Cheng, Y., Cho, E.K., Voon, P.J., Planchard, D., Su, W.C., Gray, J.E., Lee, S.M., Hodge, R., Marotti, M., Rukazenzov, Y., Ramalingam, S.S., Investigators, F., 2018. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *The New England journal of medicine* 378, 113-125.

Stark, L.A., Reid, K., Sansom, O.J., Din, F.V., Guichard, S., Mayer, I., Jodrell, D.I., Clarke, A.R., Dunlop, M.G., 2007. Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. *Carcinogenesis* 28, 968-976.

Takahashi, A., Seike, M., Chiba, M., Takahashi, S., Nakamichi, S., Matsumoto, M., Takeuchi, S., Minegishi, Y., Noro, R., Kunugi, S., Kubota, K., Gemma, A., 2018. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. *Scientific reports* 8, 14896.

Vogiatzi, P., De Falco, G., Claudio, P.P., Giordano, A., 2006. How does the human RUNX3 gene induce apoptosis in gastric cancer? Latest data, reflections and reactions. *Cancer biology & therapy* 5, 371-374.

Wield, A.M., Walsh, C.S., Rimel, B.J., Cass, I., Karlan, B.Y., Li, A.J., 2018. Aspirin use correlates with survival in women with clear cell ovarian cancer. *Gynecologic oncology reports* 25, 78-81.

Wu, D.W., Chen, C.Y., Chu, C.L., Lee, H., 2016. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. *Oncogene* 35, 621-630.

Xia, H., Lee, K.W., Chen, J., Kong, S.N., Sekar, K., Deivasigamani, A., Seshachalam, V.P., Goh, B.K.P., Ooi, L.L., Hui,

K.M., 2017. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. *Cell death discovery* 3, 17058.

Yang, Z., Yang, N., Ou, Q., Xiang, Y., Jiang, T., Wu, X., Bao, H., Tong, X., Wang, X., Shao, Y.W., Liu, Y., Wang, Y., Zhou, C., 2018. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. *Clinical cancer research : an official journal of the American Association for Cancer Research* 24, 3097-3107.

Yochum, Z.A., Cades, J., Wang, H., Chatterjee, S., Simons, B.W., O'Brien, J.P., Khetarpal, S.K., Lemtiri-Chlieh, G., Myers, K.V., Huang, E.H., Rudin, C.M., Tran, P.T., Burns, T.F., 2018. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. *Oncogene* 38, 656-670.

Yue, D., Sun, X., 2018. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. *Cell death & disease* 9, 935.

Zhang, W., Tan, Y., Ma, H., 2017. Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation. *Oncology letters* 14, 5409-5417.

Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C., 2011. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *The Lancet. Oncology* 12, 735-742.

## Figure legends

**Figure 1 Aspirin sensitizes osimertinib in osimertinib-resistant NSCLC patients and osimertinib-resistant cells.** (A) The chest CT examination showed the size of the patient's tumor reduction followed with aspirin and osimertinib concurrent treatment. (B) Summary of the gene alterations in each parental and resistant cell lines detected by next-generation sequencing. (C) Cell viability was analyzed by MTT assay in parental PC-9GR, H1975 cells and their corresponding osimertinib and rociletinib resistant cells. Mean  $\pm$  SEM. (D) Representative images

of showing the colony formation ability of resistant PC-9GROR and H1975-OR cells. Histogram showed the colony cell numbers in the indicated groups. The colony formation rates are shown as the mean  $\pm$  SD from three independent experiments. \*,  $p < 0.05$  compared with control; †,  $p < 0.05$  compared with aspirin treatment alone; ‡,  $p < 0.01$  compared with osimertinib treatment alone. (E) Ki67 proliferation assay of resistant PC-9GROR cells and H1975-OR cells with various treatment. Histogram showed the incorporation cells in the indicated groups respectively Scale bars: 100  $\mu$ m. Data are from three independent assays and are shown as the mean  $\pm$  SD. \*,  $p < 0.05$  compared with control; †,  $p < 0.05$  compared with aspirin treatment alone; ‡,  $p < 0.01$  compared with osimertinib treatment alone. DAPI, 4',6-diamidino-2-phenylindole; Asp, aspirin; Osi, osimertinib.

**Figure 2 Apoptosis reduction leads to acquired resistance to osimertinib in NSCLC cell lines.**

(A) The apoptotic parental and resistant cell lines followed with osimertinib and rociletinib treatment or not by flow cytometry. Histogram showed the percentage of apoptotic cells in the indicated groups. \*,  $p < 0.05$  compared with untreated parental cells. (B) TUNEL staining assessing parental and resistant cell apoptosis after osimertinib treated. (C) The apoptosis-related proteins were measured by western blot assay. GAPDH was used to confirm equal gel loading.

**Figure 3 Aspirin induces apoptosis to sensitize osimertinib in NSCLC cell lines.** (A) The apoptotic cells after concurrent treated with aspirin and osimertinib/ rociletinib were measured with flow cytometry in PC-9GROR, H1975-OR, PC-9GRCOR and H1975-COR respectively. Histogram showed the percentage of apoptotic cells of the indicated groups respectively. \*,  $p < 0.05$  compared with control; †,  $p < 0.05$  compared with aspirin treatment alone; ‡,  $p < 0.01$  compared with osimertinib treatment alone. Scale bars: 100  $\mu$ m. (B) TUNEL staining assessing parental and resistant cell apoptosis after aspirin and osimertinib combined treatment. (C) The critical proteins in Bcl-2 family including Bim, Mcl-2, Bcl-2 and Bax were examined by western blot assay followed with aspirin and osimertinib / rociletinib concurrent treatment in PC-9GROR,

---

H1975-OR, PC-9GRCOR and H1975-COR PC-9GROR and H1975-OR cells.

**Figure 4 Aspirin induces apoptosis dependent on Bim elevation.** (A) PC-9GROR cells were performed with osimertinib in indicated doses and time points, and Bim proteins were detected by western blot analysis. (B) PC-9GROR and H1975-OR cells were transfected with siRNA and the Bim level was detected by western blot analysis. (C) The cell viability was detected with MTT assay after knocking down Bim expression in PC-9GROR and H1975-OR cells. Histogram showing the IC<sub>50</sub> values for the indicated groups. \*, p < 0.05 compared with the siNC + osimertinib group; †, p < 0.05 compared with the siBim + osimertinib group. (D) The cell proliferation was detected by the Ki67 proliferation assay after knocking down Bim expression in PC-9GROR and H1975-OR cells. (E) The apoptotic cells were measured by flow cytometry analysis after knocking down Bim expression in PC-9GROR and H1975-OR cells. DAPI, 4',6-diamidino-2-phenylindole; NC, negative control.

**Figure 5 Inhibition of Akt and FoxO3a phosphorylation plays a crucial role in the elevation of Bim expression.** (A) Bim transcriptional level was assessed by RT-PCR in PC-9GROR and H1975OR cell with the indicated treatment. (B) The Akt and Erk proteins phosphorylation were measured by western blot assay combined treated with aspirin and osimertinib or not in PC-9GROR and H1975-OR cells. GAPDH was used to confirm equal gel loading. (C) The FoxO3a phosphorylation was measured by western blot assay combined treated with aspirin and osimertinib or not in PC-9GROR and H1975-OR cells. GAPDH was used to confirm equal gel loading. GAPDH was used to confirm equal gel loading. (D) Immuno fluorescence staining showed the subcellular localization of FoxO3a in PC-9GROR and H1975-OR cells with indicated treatments. (E) Cell viability of PC-9GROR and H1975-OR cells treated with osimertinib + aspirin + IGF-1 (200 ng/mL) for 48 h was assessed by the MTT assay. All the experiments were measured in triplicate.

**Figure 6 Combination of osimertinib and aspirin effectively inhibited the tumor growth in PC-9GROR xenografts.** (A) Tumor volume (mm<sup>3</sup>) in PC-9GROR cells with various applications

---

were shown. \*,  $p < 0.05$  compared with the control group; ‡,  $p < 0.01$  compared with the osimertinib alone group; n.s: not significant. (B) Macroscopic appearance of tumors after drug application for 5 weeks. (C) Tumor weight (g) in PC-9GROR cells with various applications were shown. \*,  $p < 0.05$  compared with the control group; ‡,  $p < 0.01$  compared with the osimertinib alone group. (D) Kaplan-Meier survival curves were presented for the aboved 3 groups. The log-rank test demonstrated a significant difference between the osimertinib plus aspirin group and the osimertinib alone group. (E) Bim, AKT and FoxO3a phosphoralation were examined from 3 tumors randomly selected from each group for western blotting. GAPDH was used as a loading control. (F) Best change from baseline in tumor size ( $n = 45$ ). Dotted lines at 20% and -30% indicate the percent change from baseline and represent progressive disease and PR respectively, per RECIST v1.1. (G) Kaplan-Meier analysis of NSCLC patients treated with osimertinib plus aspirin and osimertinib alone after the development of first-generation EGFR-TKI resistance (PFS analysis).

### **Supplementary figure legends**

**Supplementary Figure 1. The effects of different doses of aspirin on various cell lines. Cell viabilities.**

**Supplementary Figure 2. The chest CT scan presented another patient's pulmonary nodule progression.**

**Supplementary Figure 3. The effect of aspirin combined with different EGFR-TKIs in different cell lines.**

**Supplementary Figure 4. The morphological features in osimertinib sensitive- and resistant- cells with osimertinib combined with or without aspirin treatment.**

**Supplementary Figure 5. Aspirin overcome resistance by increasing Bim level in gefitinib and erlotinib resistant cell respectively.**

**Supplementary Figure 6. H1975-OR cells were performed with osimertinib concurrend with indicated doses.**

**Supplementary Figure 7. Histograms of Ki67 cell proliferation alterations and of flow cytometry cell apoptosis alterations.**

**Supplementary Figure 8. Western blotting to analyze Akt and Erk phosphorylation in PC-9GR, H1975, H1650-M3, PC-9GRCOR and H1975COR cell lines.**

**Supplementary Figure 9. The expression of AKT, p-AKT, FoxO3a, p-FoxO3a, Bim were measured by western blot assay in PC-9GROR and H1975-OR cell lines.**

**Supplementary Figure 10. The nude mice body weight.**


---

**Supplementary Figure 11. PGE2 secretion in osimertinib parental- and resistant- cells with ELISA assay.**

**Supplementary Figure 12. The schematic diagram for the mechanism that aspirin overcomes osimertinib resistance.**

**Supplementary Table 1. The Patient Characteristics of 45 patients presenting with NSCLC.**


**A**




**B**

Cell lines	Del19	L858R	T790M	EGFR amplification	Met amplification	BRAF amplification
PC-9GR	+	-	+	-	-	-
PC-9GROR	+	-	+	-	-	-
H1975	-	+	+	-	-	-
H1975-OR	-	+	+	-	+	-

**C**



**D**



**E**

